Article
Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology
21 Nov 2012
Abstract excerpt
BACKGROUND: An antibody with cross-reactivity can create unexpected side effects or false diagnostic reports if used for clinical purposes. ERCC1 is being explored as a predictive diagnostic biomarker for cisplatin-based chemotherapy. High ERCC1 expression is linked to drug resistance on cisplatin-based chemotherapy. 8F1 is one of the most commonly used monoclonal antibodies for evaluating ERCC1 expression levels...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
